Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $84.91

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has received a consensus rating of “Buy” from the fourteen analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $84.9091.

A number of equities analysts have issued reports on MIRM shares. Stifel Nicolaus set a $89.00 target price on Mirum Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 11th. Citizens Jmp upped their price objective on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company a “market outperform” rating in a research note on Wednesday, November 5th. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Wednesday, November 5th. Evercore ISI upped their price target on shares of Mirum Pharmaceuticals from $77.00 to $89.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Finally, HC Wainwright lifted their price target on shares of Mirum Pharmaceuticals from $80.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th.

Mirum Pharmaceuticals Trading Down 0.2%

MIRM opened at $69.88 on Friday. The company’s 50 day moving average is $71.73 and its 200-day moving average is $62.55. The company has a market cap of $3.59 billion, a P/E ratio of -81.25 and a beta of 0.42. Mirum Pharmaceuticals has a 1-year low of $36.88 and a 1-year high of $78.54. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The firm had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The company’s quarterly revenue was up 47.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.30) earnings per share. Equities research analysts predict that Mirum Pharmaceuticals will post -1.43 earnings per share for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt sold 9,578 shares of the stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $76.01, for a total value of $728,023.78. Following the completion of the sale, the chief financial officer owned 39,945 shares of the company’s stock, valued at approximately $3,036,219.45. This represents a 19.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Laura Brege sold 17,000 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $74.40, for a total value of $1,264,800.00. Following the completion of the sale, the director owned 15,703 shares in the company, valued at $1,168,303.20. The trade was a 51.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 22.87% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. boosted its position in Mirum Pharmaceuticals by 3.4% during the first quarter. Frazier Life Sciences Management L.P. now owns 6,795,121 shares of the company’s stock valued at $306,120,000 after acquiring an additional 224,729 shares during the last quarter. Eventide Asset Management LLC boosted its position in shares of Mirum Pharmaceuticals by 4.4% during the 2nd quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock valued at $134,224,000 after purchasing an additional 110,485 shares in the last quarter. Vanguard Group Inc. grew its stake in Mirum Pharmaceuticals by 4.8% during the first quarter. Vanguard Group Inc. now owns 2,540,061 shares of the company’s stock worth $114,430,000 after purchasing an additional 115,327 shares during the period. Geode Capital Management LLC grew its stake in Mirum Pharmaceuticals by 6.8% during the second quarter. Geode Capital Management LLC now owns 1,029,616 shares of the company’s stock worth $52,405,000 after purchasing an additional 65,951 shares during the period. Finally, Wellington Management Group LLP lifted its stake in Mirum Pharmaceuticals by 566.8% in the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after buying an additional 672,118 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.